CTLA4 and melanoma: Early studies by Wolchok et al. investigated the effectiveness of anti-CTLA-4 and PD-1 combination therapy compared with monotherapy or sequential treatment using anti-CTLA-4 blockade followed by anti-PD-1 checkpoint blockade in unresectable melanoma patients.